Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy

2 Jul 2025

Abstract excerpt

Mutated oncogenic Kirsten rat sarcoma virus (KRAS) antigen is expressed in a large variety of cancers, including pancreatic, colorectal, and pulmonary cancers. The oncogenic KRAS mutations cause malignancies and are usually ubiquitously expressed by all cells of a tumor. The KRAS amino acid substitutions at the positions 12 or 13 are among the most frequent mutations in human cancers. Here, we developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Cancer Research and Treatments
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40603894
DOI: 10.1038/s41598-025-05134-6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapyPMID 40603894Read ↗

Preclinical development of a mutant KRAS targeting therapeutic cancer vaccine.Semantic proximity Read ↗

Cancer vaccines: Targeting KRAS-driven cancers.Semantic proximity Read ↗

Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity Read ↗

DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.Semantic proximity Read ↗

Targeting the undruggable oncogenic KRAS: the dawn of hope.Semantic proximity Read ↗

KRAS Mutations in Cancer: Understanding Signaling Pathways to Immune Regulation and the Potential of ImmunotherapySemantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.Semantic proximity Read ↗

Intracellular Delivery of Anti-Kirsten Rat Sarcoma Antibodies Mediated by Polymeric Micelles Exerts Strong In Vitro and In Vivo Anti-Tumorigenic Activity in Kirsten Rat Sarcoma-Mutated Cancers.Semantic proximity Read ↗

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumorsSemantic proximity Read ↗

Exploring the therapeutic potential of precision T-Cell Receptors (TCRs) in targeting KRAS G12D cancer through in vitro development.Semantic proximity Read ↗

Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.